Eligible individuals include those who are known carriers of mutations such as BRCA1 and BRCA2, TP53, PTEN, and CDH1, those who have first-degree relatives with these mutations and have opted not to undergo genetic testing, those who have undergone risk assessment by a genetic clinic using the IBIS model or BODICEA and have a personal lifetime risk of breast cancer of 25% or higher, or those who have received radiotherapy to the chest before the age of 30 at least 8 years prior [4]. This evidence concerns the gene BRCA2 and breast cancer.